Eprontia Prices, Coupons, Copay Cards & Patient Assistance
Eprontia (topiramate) is a member of the carbonic anhydrase inhibitor anticonvulsants drug class and is commonly used for Epilepsy, Lennox-Gastaut Syndrome, Migraine Prevention, and others.
This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Eprontia prices
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Eprontia Coupons, Copay Cards and Rebates
Eprontia offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Eprontia eVocherRx Program
Eligible commercially insured patients may pay $0 per prescription at a participating pharmacy.
- Applies to:
- Eprontia
- Number of uses:
- Per prescription until program expires
Form more information phone: 844-472-2032 or Visit website
Eprontia Bridge Drug Program
Eligible commercially insured patients experiencing an insurance delay longer than 48 hours may be able to receive up to 30 days of medication at no cost.
- Applies to:
- Eprontia
- Number of uses:
- Temporary Assistance
Form more information phone: 844-472-2032 or Visit website
Patient Assistance & Copay Programs for Eprontia
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Eprontia (topiramate) Solution; Oral
More information please phone: 866-316-7263 Visit Website
Provider: Azurity Solutions: Eprontia
Eligibility requirements:- Determined case by case
- Based on FPL
- Medically Necessary as determined by a Doctor
- Must be treated by US licensed healthcare provider
- Patient must sign the enrollment form to give the program permission to access their financial information in order to determine eligibility. Co-payment assistance, reimbursement support, and patient assistance programs are available for eligible patients. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
- Eprontia (topiramate) Solution; Oral
More information please phone: 844-472-2032 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Eprontia (topiramate)
- Eprontia consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- Breastfeeding
- En español